

Product Information Sheet

Human CYP3A5BR Bactosomes

Catalogue Number: CYP048

Product Description: Human CYP3A5 and human CYP-reductase coexpressed in Escherichia coli,

supplemented with purified human cytochrome b5

Amount: 1 nmol cytochrome P450

Storage Buffer: 50 mM Tris-acetate (pH 7.6), 250 mM sucrose, 0.25 mM EDTA

Storage: Store at -80°C. Avoid frequent temperature changes. Thaw on ice.

Intended Use: For laboratory (research) purposes only.

Batch Number:C3A5BR002/AP450 Concentration:1.4 nmol/mlCytochrome b_5 Concentration:6.9 nmol/mlProtein Concentration:13.3 mg/ml

Specific P450 Content: 105 pmol/mg protein

Cytochrome c Reductase Activity: 1538 nmol/min/mg protein

¹P450 Activity Data

Activity: Testosterone 6β-hydroxylase

²Linear with time up to: 8 min ³Linear with P450 up to: 20 pmol/ml

V_{max}: 102 pmol/min/pmol CYP

 K_m : 72 μ M

Approved by ______ Date _____9th January, 2019

Notes:

Safety Data

The toxicological properties of this reagent have not been investigated. Exercise due care when handling.

IMPORTANT DISCLAIMER

- 1. Products supplied by Cypex may be harmful if misused. Any product ordered from Cypex must not be used for any purpose other than the intended use specified on the Product Information Sheet which accompanies the product when delivered. Please ensure that products supplied by Cypex are used safely, and, in particular, that the products do not come into direct human contact.
- 2. Cypex undertakes that all products supplied by it shall conform to the specification appearing on the Product Information Sheet which accompanies the product when delivered. In the event that products supplied by Cypex fail to meet such specification, Cypex will supply replacement products free of charge provided that the defective products have been returned to Cypex within a reasonable time of delivery (Cypex will reimburse reasonable costs incurred in returning defective products), and this shall be the only remedy available in respect of the supply of any defective products.
- 3. Cypex gives no undertakings or warranties in respect of products supplied other than the undertaking given at 2, above. Furthermore, Cypex has given and gives no undertaking or warranty nor does it make any representation, directly or indirectly, express or implied, about the quality, character or suitability of products supplied by Cypex.
- 4. Cypex shall have no liability in respect of loss or damage (whether direct or indirect or in the nature of loss of profit) suffered as a result of the supply of products by Cypex, or the subsequent use, storage or other application of the products, whether or not the products meet the specification referred to at 2, above.

Produced under licence from BTG International Limited (AU730155, EP0914446, US6566108 and other patents pending). United States Patent Nos. 5,420,027 or 5,240,831, Canada Patent No. 2100245 and other patents pending.

¹Unless otherwise stated, all assays are carried out at 37°C in 100 mM potassium phosphate buffer (pH 7.4) containing 5 mM magnesium chloride and an NADPH generating system [5 mM glucose 6-phosphate, 1 mM NADP⁺, 1 U/ml glucose 6-phosphate dehydrogenase].

²Determined at 60 µM substrate, using a P450 concentration of 5 pmol/ml.

³Determined at 60 µM substrate, using an incubation time of 5 min.